March 18, 2015- Op-Ed by Steven E. Greer, MD The American College of Cardiology (ACC) meeting is underway, and the main Late Breaking data making the national news came from the PCSK9-antibody drugs (evolocumab and alirocumab) that dramatically lower LDL cholesterol. Presumably, LDL is a reliable surrogate marker for heart disease, according to the studies […]
↧